1
|
Sia TY, Yaari Z, Feiner R, Smith E, Da Cruz Paula A, Selenica P, Doddi S, Chi DS, Abu-Rustum NR, Levine DA, Weigelt B, Fleisher M, Ramanathan LV, Heller DA, Long Roche K. Uterine washings as a novel method for early detection of ovarian cancer: Trials and tribulations. Gynecol Oncol Rep 2024; 51:101330. [PMID: 38356691 PMCID: PMC10865230 DOI: 10.1016/j.gore.2024.101330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2023] [Revised: 01/25/2024] [Accepted: 01/29/2024] [Indexed: 02/16/2024] Open
Abstract
Given the tubal origin of high-grade serous ovarian cancer (HGSC), we sought to investigate intrauterine lavage (IUL) as a novel method of biomarker detection. IUL and serum samples were collected from patients with HGSC or benign pathology. Although CA-125 and HE4 concentrations were significantly higher in IUL samples compared to serum, they were similar between IUL samples from patients with HGSC vs benign conditions. In contrast, CA-125 and HE4 serum concentrations differed between HGSC and benign pathology (P =.002 for both). IUL and tumor samples from patients with HGSC were subjected to targeted panel sequencing and droplet digital PCR (ddPCR). Tumor mutations were found in 75 % of matched IUL samples. Serum CA-125 and HE4 biomarker levels allowed for better differentiation of HGSC and benign pathology compared to IUL samples. We believe using IUL for early detection of HGSC requires optimization, and current strategies should focus on prevention until early detection strategies improve.
Collapse
Affiliation(s)
- Tiffany Y Sia
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Zvi Yaari
- School of Pharmacy, Department of Medicine, Hebrew University of Jerusalem, Israel
| | - Ron Feiner
- Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Evan Smith
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Arnaud Da Cruz Paula
- i3S Instituto de Investigação e Inovação em Saúde, Porto, Portugal
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Pier Selenica
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Sital Doddi
- Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Dennis S Chi
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Department of OB/GYN, Weill Cornell Medical College, New York, NY, USA
| | - Nadeem R Abu-Rustum
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Department of OB/GYN, Weill Cornell Medical College, New York, NY, USA
| | | | - Britta Weigelt
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Martin Fleisher
- Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Lakshmi V Ramanathan
- Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Daniel A Heller
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Department of Pharmacology, Weill Cornell Medical College, Cornell University, New York, NY, USA
| | - Kara Long Roche
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Department of OB/GYN, Weill Cornell Medical College, New York, NY, USA
| |
Collapse
|
2
|
Wu Y, Wang C, Wang C, Wang P, Chang X, Han L, Zhang Y. Multiple Biomarker Simultaneous Detection in Serum via a Nanomaterial-Functionalized Biosensor for Ovarian Tumor/Cancer Diagnosis. MICROMACHINES 2022; 13:mi13122046. [PMID: 36557345 PMCID: PMC9783278 DOI: 10.3390/mi13122046] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Revised: 11/18/2022] [Accepted: 11/19/2022] [Indexed: 06/12/2023]
Abstract
Ovarian tumors/cancers are threatening women's health worldwide, which demands high-performance detection methods and accurate strategies to effectively detect, diagnose and treat them. Here, we report a nanographene oxide particle-functionalized microfluidic fluorescence biosensor to simultaneously detect four biomarkers, CA125, HE4, CEA and APF, for ovarian tumor/cancer diagnosis. The developed biosensor exhibits good selectivity and a large biomarker detection range with a limit of detection of 0.01 U/mL for CA125 and ~1 pg/mL for HE4, CEA and APF. The current results indicate that (1) the proposed biosensor is a promising tool for the simultaneous detection of multiple biomarkers in ovarian tumors/cancer and (2) CA125 and HE4 are strong indicators, AFP may be helpful, and CEA is a weak biomarker for ovarian tumor/cancer diagnosis. The proposed biosensor would be a potential tool, and an analytical approach for the simultaneous detection of multiple biomarkers will provide a new strategy for the early screening, diagnosis and treatment of ovarian tumors/cancers, as well as other cancers.
Collapse
Affiliation(s)
- Yu Wu
- Peking University Third Hospital, Haidian District, Beijing 100191, China
| | - Chunhua Wang
- Institute of Marine Science and Technology, Shandong University, Qingdao 266273, China
| | - Chao Wang
- Institute of Marine Science and Technology, Shandong University, Qingdao 266273, China
| | - Pan Wang
- Peking University Third Hospital, Haidian District, Beijing 100191, China
| | - Xiaohan Chang
- Peking University Third Hospital, Haidian District, Beijing 100191, China
| | - Lin Han
- Institute of Marine Science and Technology, Shandong University, Qingdao 266273, China
- Shenzhen Research Institute of Shandong University, Shenzhen 518057, China
- Shandong Engineering Research Center of Biomarker and Artificial Intelligence Application, Jinan 250100, China
| | - Yu Zhang
- Institute of Marine Science and Technology, Shandong University, Qingdao 266273, China
- Shenzhen Research Institute of Shandong University, Shenzhen 518057, China
| |
Collapse
|
3
|
Wu Y, Wang C, Wang P, Wang C, Zhang Y, Han L. A high-performance microfluidic detection platform to conduct a novel multiple-biomarker panel for ovarian cancer screening. RSC Adv 2021; 11:8124-8133. [PMID: 35423342 PMCID: PMC8695074 DOI: 10.1039/d0ra10200h] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Accepted: 01/30/2021] [Indexed: 11/22/2022] Open
Abstract
Ovarian cancer is an important leading cause of cancer-related deaths among females, and a single biomarker does not have the sensitivity and specificity required for an effective ovarian cancer screening. Herein, we investigate a high-performance microfluidic detection platform to conduct a novel panel of multiple biomarkers for the early detection of ovarian carcinoma, which include CA125, HE4, OPN, MSLN, Hsp70, CA153, AFP, IL-6, and IL-8 using a microfluidic chip. High-throughput microfluidic chips and graphene oxide-assembled substrate are used to microprint repeatable capture antibody arrays and conduct multiple biomarkers in microscale volume samples. The proposed microfluidic platform achieves an ultralow detection limit of ∼1 pg mL−1 and 0.01 U mL−1 with excellent detection selectivity and a short detection time of 30 min. The analysis of serum biomarkers in 18 ovarian cancer patients and 4 healthy persons indicates a clear subgroup sorting between the high-grade serous ovarian carcinoma, borderline, and benign tumor patients, and healthy persons. The proposed detection platform and the biomarker panel are promising to conduct an early detection of ovarian cancer. A high-performance microfluidic detection platform is developed to conduct a novel panel of multiple biomarkers for the early detection of ovarian carcinoma, which is promising for the early detection of ovarian cancer.![]()
Collapse
Affiliation(s)
- Yu Wu
- Peking University Third Hospital
- Beijing 100191
- China
| | - Chunhua Wang
- Institute of Marine Science and Technology
- Shandong University
- Qingdao 266273
- China
| | - Pan Wang
- Peking University Third Hospital
- Beijing 100191
- China
| | - Chao Wang
- Institute of Marine Science and Technology
- Shandong University
- Qingdao 266273
- China
| | - Yu Zhang
- Institute of Marine Science and Technology
- Shandong University
- Qingdao 266273
- China
| | - Lin Han
- Institute of Marine Science and Technology
- Shandong University
- Qingdao 266273
- China
| |
Collapse
|
4
|
Williams RM, Lee C, Galassi TV, Harvey JD, Leicher R, Sirenko M, Dorso MA, Shah J, Olvera N, Dao F, Levine DA, Heller DA. Noninvasive ovarian cancer biomarker detection via an optical nanosensor implant. SCIENCE ADVANCES 2018; 4:eaaq1090. [PMID: 29675469 PMCID: PMC5906074 DOI: 10.1126/sciadv.aaq1090] [Citation(s) in RCA: 88] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/02/2017] [Accepted: 03/06/2018] [Indexed: 05/20/2023]
Abstract
Patients with high-grade serous ovarian carcinoma (HGSC) exhibit poor 5-year survival rates, which may be significantly improved by early-stage detection. The U.S. Food and Drug Administration-approved biomarkers for HGSC-CA-125 (cancer antigen 125) and HE4 (human epididymis protein 4)-do not generally appear at detectable levels in the serum until advanced stages of the disease. An implantable device placed proximal to disease sites, such as in or near the fallopian tube, ovary, uterine cavity, or peritoneal cavity, may constitute a feasible strategy to improve detection of HGSC. We engineered a prototype optical sensor composed of an antibody-functionalized carbon nanotube complex, which responds quantitatively to HE4 via modulation of the nanotube optical bandgap. The complexes measured HE4 with nanomolar sensitivity to differentiate disease from benign patient biofluids. The sensors were implanted into four models of ovarian cancer, within a semipermeable membrane, enabling the optical detection of HE4 within the live animals. We present the first in vivo optical nanosensor capable of noninvasive cancer biomarker detection in orthotopic models of disease.
Collapse
Affiliation(s)
| | - Christopher Lee
- Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Thomas V. Galassi
- Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- Weill Cornell Medicine, Cornell University, New York, NY 10065, USA
| | - Jackson D. Harvey
- Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- Weill Cornell Medicine, Cornell University, New York, NY 10065, USA
| | - Rachel Leicher
- Tri-Institutional Program in Chemical Biology, New York, NY 10065, USA
- The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA
| | - Maria Sirenko
- Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Madeline A. Dorso
- Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- Weill Cornell Medicine, Cornell University, New York, NY 10065, USA
| | - Janki Shah
- Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Narciso Olvera
- Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY 10016, USA
| | - Fanny Dao
- Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY 10016, USA
| | - Douglas A. Levine
- Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY 10016, USA
| | - Daniel A. Heller
- Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- Weill Cornell Medicine, Cornell University, New York, NY 10065, USA
- Corresponding author.
| |
Collapse
|